Beckman Coulter to Issue $500M in New Debt for Olympus Dx Acquisition

The $800 million acquisition will strengthen Beckman Coulter's presence in the clinical chemistry market. The firm does not anticipate a change in its current investment grade ratings due to the new debt.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.